- 2024,11,05
On the evening of October 8th, Cheng Yi Pharmaceutical released a repurchase report, stating that the company plans to use its own funds to repurchase shares through centralized bidding trading. The total repurchase funds will not be less than RMB 50 million (inclusive) and not exceed RMB 100 million (inclusive), and the repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase price of the shares shall not exceed RMB 9.66 per share (inclusive). The repurchase period is within 12 months from the date of approval of the share repurchase plan by the company's board of directors.
Cheng Yi Pharmaceutical stated that this share repurchase is based on confidence in the company's future development and high recognition of its value. It will help establish and improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of employees, enhance team cohesion and competitiveness, and effectively integrate shareholder interests, company interests, and employee interests.
On the same evening, Cheng Yi Pharmaceutical also released a progress announcement on the repurchase. According to the announcement, on October 8th, Cheng Yi Pharmaceutical repurchased 2.403 million shares of the company's stock for the first time through centralized bidding trading, accounting for 0.73% of the company's current total share capital. The highest purchase price was 8.36 yuan/share, the lowest purchase price was 8.03 yuan/share, and the total amount paid was 19.7862 million yuan (excluding transaction fees).
Source:Securities Daily Online